A new 3D-printed fabrication approach means a cleanroom is now optional ...

Drug Substance manufacturing is a critical component of pharmaceutical production, requiring precise processes, rigorous quality control, and innovative solutions to overcome various challenges. From ...

Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...

New draft guidance issued by the US Food and Drug Administration (FDA) is intended to clarify which changes to a pharmaceutical company's manufacturing process must be reported to federal regulators, ...

Quality by design is critical for cell and gene therapy manufacturing where process controls directly influence product ...

The development of continuous pharmaceutical manufacturing is crucial and can be analyzed via advanced computational models. Machine learning is a strong computational paradigm that can be integrated ...

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...

From the moment we could look up to the skies, humanity has dreamt of what’s up there. And once we got there, how could we master it? And now that we’re there all the time, how can we use it? In 2025, ...

Researchers at the University of Liège (BE) have designed a high-performance, open-access continuous flow process to safely produce key antibacterial drugs from bio-based furfural. The results of the ...

Pharmacy benefit managers received substantial attention during 2024. Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and related profits. As a new ...

Adam Kovalčík showed off a poster about his research at the Regeneron International Science and Engineering Fair in Columbus, Ohio.Chris Ayers Photography/Licensed by Society for Science When Adam ...

A Class II recall was initiated for duloxetine lots after N-nitroso-duloxetine exceeded FDA intake limits, reflecting low acute clinical risk but regulatory nonconformance. Nitrosamine issues ...